News & Updates

Show Multimedia Only

Treatment de-escalation safe in patients with ERBB2-positive early breast cancer and high TILs

13 May 2026 by

De-escalation of chemotherapy dose and trastuzumab duration may not increase the risk of distant relapse or death in patients with ERBB2-positive (also referred to as HER2-positive) early breast cancer and tumour infiltrating lymphocyte (TIL) levels of ≥20 percent, according to a 10-year analysis of the phase III ShortHER trial.

Treatment de-escalation safe in patients with ERBB2-positive early breast cancer and high TILs

13 May 2026

[HKU Medical Grand Rounds] Angels and demons: Immunotherapy for treatment of metastatic non-small-cell lung cancer

17 Mar 2026 by

Immunotherapy is gaining increasing attention in Oncology. It works by stimulating or modulating the immune system to fight malignant tumours. While immunotherapy can achieve favourable response in many cancers, it also carries the risk of severe, or even life-threatening, immune-related adverse events (IRAEs). Here we present two cases of metastatic non-small-cell lung cancer (NSCLC) demonstrating how immunotherapy can be the angel and demon of cancer medicines.

[HKU Medical Grand Rounds] Angels and demons: Immunotherapy for treatment of metastatic non-small-cell lung cancer

17 Mar 2026

‘Sandwich’ sequencing of adjuvant chemoradiation tied to less toxicity in advanced endometrial cancer

17 Mar 2026

Survival and clinical outcomes in patients with advanced stage endometrial cancer are comparable among the different sequences of adjuvant chemotherapy and radiation therapy, a recent study has shown. However, “sandwich” therapy results in less chronic toxicity, which provides an opportunity for a better quality of life in survivorship.

‘Sandwich’ sequencing of adjuvant chemoradiation tied to less toxicity in advanced endometrial cancer

17 Mar 2026

Achieving durable response with PD-1 inhibitor therapy in relapsed metastatic squamous cell lung cancer

24 Feb 2026 by

A 71-year-old male former smoker, who quit smoking in 2014, presented with cough in February 2015. CT and PET-CT scans in March 2015 showed T4N0M0 disease (stage IIIA), with an 8 cm hypermetabolic soft tissue mass at the right upper lobe (RUL) of the lung. Mild activity was also noted in the right hilar lymph node region.

Achieving durable response with PD-1 inhibitor therapy in relapsed metastatic squamous cell lung cancer

24 Feb 2026

How does AKYNZEO®(netupitant/palonosetron) works

28 Aug 2025

How does AKYNZEO®(netupitant/palonosetron) works

28 Aug 2025

TXA use in radical cystectomy reduces bleeding, need for blood transfusion

12 May 2025

Using tranexamic acid (TXA) appears to lessen blood loss and the need for perioperative blood transfusion (PBT) without increasing the risk of venous thromboembolism (VTE) in patients with bladder cancer undergoing radical cystectomy, reports a study.

TXA use in radical cystectomy reduces bleeding, need for blood transfusion

12 May 2025

EGFR gene mutation abundance predicts survival in NSCLC patients

03 Apr 2025

In patients with nonsmall cell lung cancer (NSCLC), plasma epidermal growth factor receptor (EGFR) mutation abundance shows a significant association with survival benefit, reveals a study.

EGFR gene mutation abundance predicts survival in NSCLC patients

03 Apr 2025

Cetuximab linked to pocket infections after central venous port placement

02 Apr 2025

Cetuximab therapy appears to induce skin complications in patients following central venous port placement, reports a study.

Cetuximab linked to pocket infections after central venous port placement

02 Apr 2025

What’s new in advanced urothelial carcinoma?

02 Apr 2025 by

Enfortumab vedotin and pembrolizumab’s (EV+P) EV-302 trial results represent a major advancement in metastatic urothelial carcinoma (mUC), including in Asian patients, according to Professor Ravindran Kanesvaran of the National Cancer Centre in Singapore, who also discussed managing skin toxicity associated with this regimen and provided an overview of other agents for UC under investigation at Uro-Oncology Asia 2025.

What’s new in advanced urothelial carcinoma?

02 Apr 2025

Better NPC risk stratification with identification of distinct EBV DNA molecular features

01 Apr 2025 by

A research team from the Faculty of Medicine, Chinese University of Hong Kong (CUHK) has identified molecular features in Epstein-Barr virus (EBV) DNA specifically associated with nasopharyngeal cancer (NPC) that differ significantly from the EBV DNA found in individuals with general EBV infections.

Better NPC risk stratification with identification of distinct EBV DNA molecular features

01 Apr 2025

News & Updates

Showing Oncology articles

Showing

Specialty:

Treatment de-escalation safe in patients with ERBB2-positive early breast cancer and high TILs

Treatment de-escalation safe in patients with ERBB2-positive early breast cancer and high TILs

[HKU Medical Grand Rounds] Angels and demons: Immunotherapy for treatment of metastatic non-small-cell lung cancer

[HKU Medical Grand Rounds] Angels and demons: Immunotherapy for treatment of metastatic non-small-cell lung cancer

‘Sandwich’ sequencing of adjuvant chemoradiation tied to less toxicity in advanced endometrial cancer

‘Sandwich’ sequencing of adjuvant chemoradiation tied to less toxicity in advanced endometrial cancer

Achieving durable response with PD-1 inhibitor therapy in relapsed metastatic squamous cell lung cancer

Achieving durable response with PD-1 inhibitor therapy in relapsed metastatic squamous cell lung cancer

How does AKYNZEO®(netupitant/palonosetron) works

How does AKYNZEO®(netupitant/palonosetron) works

TXA use in radical cystectomy reduces bleeding, need for blood transfusion

TXA use in radical cystectomy reduces bleeding, need for blood transfusion

EGFR gene mutation abundance predicts survival in NSCLC patients

EGFR gene mutation abundance predicts survival in NSCLC patients

Cetuximab linked to pocket infections after central venous port placement

Cetuximab linked to pocket infections after central venous port placement

What’s new in advanced urothelial carcinoma?

What’s new in advanced urothelial carcinoma?

Better NPC risk stratification with identification of distinct EBV DNA molecular features

Better NPC risk stratification with identification of distinct EBV DNA molecular features